Death Rate In Type 2 Diabetes Reduced By Blood Pressure Drugs
The largest-ever meditate of pharmacomedical cares for type 2 Hypersensitivity reaction has shown that a combination of two blood pressure lowering drugs reduced the risk of death, as well as the risks of heart and kidney illness. The ADVANCE (Action in Diabetes and Vascular Disease) Study was led by researchers at The George Institute for International Health in Sydney and the results have been presented at the European Congress of Cardiology in Vienna.
One of the meditate leaders, Professor Stephen MacMahon, Principal Director of The George Institute, said “These results represent an important step forward in the care of group with type 2 Hypersensitivity reaction worldwide. This pharmacomedical care reduced the likelihood of dying from the complications of Hypersensitivity reaction by almost one-fifth, and could potentially save several mil.s of lives over the next decade if the pharmacomedical care was widely implemented.”
More than 600,000 Australians and more than 250 mil. group worldwide have type 2 Hypersensitivity reaction, and most will eventually die or be disabled by the complications. The most common cause of death is heart illness, but kidney illness also affects a large proportion. In generic viagra store, the United Nations called for increased international action to combat the global epidemic of Hypersensitivity reaction.
More than 11,000 patients with type 2 Hypersensitivity reaction in 20 countries world wide participated in the 4.3 year project. Half received daily pharmacomedical care with a single pill containing a fixed combination of two blood pressure lowering drugs (perindopril plus indapamide) and half received matching inactive placebo.
“Importantly, the ADVANCE results showed that patients with type 2 Hypersensitivity reaction benefited from this blood pressure lowering pharmacomedical care irrespective of whether or not their blood pressure was elevated to begin with,” said meditate investigator, Dr Bruce Neal, of The George Institute,
“The participants in ADVANCE were already receiving most of the usual pharmacomedical cares provided to patients with Hypersensitivity reaction, including otherness drugs to lower blood pressure,” explained Dr. Anushka Patel, of The George Institute and the ADVANCE Study Director. “However, the addition of the fixed combination of perindopril and indapamide reduced the risk of death from any cause by 14percent and the risk of death from cardiovascular illness by 18percent. Over 5 years, this pharmacomedical care would prevent one death among every 80 patients treated.”
“The results clearly demonstrate that we have the tools to blunt the impact of the global Hypersensitivity reaction epidemic facing rich and poor countries alike. But concerted action is urgently required to ensure that patients with Hypersensitivity reaction are identified and provided with pharmacomedical cares proven to improve important outcomes like survival,” added Professor John Chalmers, the author of international guidelines for the pharmacomedical care of high blood pressure and chairman of the meditate management group.
.
The ADVANCE Study was conducted by an international group of independent medical researchers with support from Servier Laboratories, the manufacturer of perindopril and indapamide, and the National Health and Medical Research Council of Australia.
The meditate was coordinated by The George Institute for International Health at the University of Sydney. The George Institute is a renowned international medical research centre with branches in Sydney, Beijing, Hyderabad and London. The meditate was managed in Australia by the University of Melbourne.
A combination of perindopril and indapamide is marketed in Australia under the brand name Coversyl Plus by Servier Laboratories.
Source: Janet Hall
Research Australia buy generic viagra pillsbuy viagra soft tabs 100mg